Navigation Links
Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Date:10/25/2007

MTD in NSCLC Identified; Phase 2 Study Planned

WESTMINSTER, Colo., Oct. 25 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that results from three PDX studies were presented as posters during the 2007 AACR-NCI-EORTC conference held October 22-26, 2007 in San Francisco, California. The posters described the effects of PDX (pralatrexate) in patients with non-small cell lung cancer (NSCLC), in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease, and in human cancer models in vivo and in vitro.

PDX in NSCLC (Phase 1)

The poster entitled "Phase 1 study of the antifolate pralatrexate when given with vitamin B12 and folic acid supplementation in patients with advanced non-small cell lung cancer (NSCLC)" presented results of this Phase 1 dose ranging study. In the study, a total of 22 patients with relapsed or refractory NSCLC were treated at doses of 150 to 325 mg/m2 of PDX. The maximum tolerated dose (MTD) was determined to be 270 mg/m2, which is twice that observed in a previous Phase 1 study in which PDX was administered without vitamin supplementation. Clinically significant radiologic responses were observed. Greater than 50% of patients (13/22) received two or more prior treatment regimens. Based on PDX clinical experience to date, the Company plans to initiate a randomized Phase 2 study of PDX in patients with NSCLC.

PDX in NHL (Phase 1/2)

The poster entitled "A Phase '2-1-2' Study of Two Different Doses and Schedules of Pralatrexate, A High Affinity Substrate for the Redu
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The TripleMaster PCR System for three different amplifications
2. Cloning Based on Efficient Three-Fragment Assembly DNA Ligation
3. Three Micron TSK-GEL ODS-100V Columns for High Throughput LCMS
4. Three finalists named for UW-Madison CIO
5. Three state businesses receive technology grants
6. Leading cancer institute to install three TomoTherapy systems
7. Waukesha considers wireless bids from three firms
8. Computerworld top 100 includes three Wisconsin CIOs
9. 30 days to success: Three simple steps to create your own international startup
10. Three firms get state tech development grants
11. Three more Wisconsin firms to present at venture forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp Biopharmaceutical,s ... ZMapp™ antibody therapeutic to fight the Ebola outbreak ... and time-consuming the production of pharmaceuticals can be, ... publisher said that while some may be taken ... compound, those with industry knowledge are well aware ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
(Date:10/20/2014)... Rochelle, Virginia (PRWEB) October 20, 2014 ... of NDA Partners LLC, announced today that Ellen ... and legal support for the pharmaceutical industry, has ... and manager of its legal services practice. ... reports and expert witness and testimony, to top ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Capabilities ... & Team, CANTON, Mass. and BATON ROUGE, ... successful regenerative medicine,company, announced today the strategic acquisition ... develops "designer scaffolds" for the,purposes of regenerative medicine, ...
... RESEARCH TRIANGLE PARK, N.C., Feb. 25 ... tools for signal,transduction analysis, announced today that ... flagmanship technology, the FACTORIAL(TM). In,advance online publication ... colleagues describes a novel and remarkably consistent ...
... Feb. 25 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... initiated,its first Phase 3 clinical trial with ... candidate being developed for the treatment of,acute ... disorder. Alexza,believes the novel, non-invasive nature and ...
Cached Biology Technology:Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc. 2Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc. 3Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 2Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5
(Date:10/15/2014)... The Ebola virus is spreading rapidly and to an ... experienced in the past and the virus shows a ... been recorded before. For this reason, the German National ... of Science and Engineering, and the Union of the ... statement on the Ebola epidemic today. , In the ...
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology ... today announced the availability of the VeriLook ... Surveillance 3.0 provides real-time biometric face identification using ... digital surveillance cameras. The new version not only ... differentiates people from objects while they are moving ...
(Date:10/14/2014)... fly genome for the first time, revealing robust immune ... thrives in pathogen-rich dung piles and garbage heaps. , ... Genome Biology , will increase understanding of house fly ... to resist insecticides, which could lead to novel control ... transmit more than 100 human and animal diseases, including ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2
... awarded two Clemson chemistry faculty nearly $1 million to ... McNeill and Ken Christensen will receive the $960,000 grant ... in live cells. The development of techniques for ... could use this technology to determine the bodys defenses ...
... Mo. Heart disease is the leading cause of ... quality and length of life for individuals with specific ... gene and/or stem cell therapy could help a variety ... have been unsure whether the heart could benefit from ...
... the superhero cure for viral infections, may be ... infections in immunocompromised patients, according to an article ... Fungal infections (mycoses) were once seen as exotic ... life-threatening in healthy patients, fungal infections are a ...
Cached Biology News:NIH recognizes Clemson nanotechnology for molecule tracking 2Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart 2Gamma interferon could aid fight against fungal infections 2
... Ease of Use : GeneTraffic ... software tool for biological research. GeneTraffic provides ... to validate your data prior to analysis. ... Quickly define your projects using the MIAME ...
... rigid macroporous hydrophilic media. The rigid polymer ... pressures, while the macroporous beads enhance access ... reduces nonspecific binding. Macro-Prep High Q support ... very high flow rates and resolution. It ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... IDS 25-Hydroxy Vitamin D kit is ... determination of 25-hydroxyvitamin D (25-OH D) ... serum or plasma. Our patented DIRECT ... solvent precipitation and centrifugation and therefore ...
Biology Products: